Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Liabilities and Shareholders Equity: 2019-2024

Historic Liabilities and Shareholders Equity for Silence Therapeutics (SLN) over the last 6 years, with Dec 2024 value amounting to $202.6 million.

  • Silence Therapeutics' Liabilities and Shareholders Equity rose 19.53% to $146.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $700.0 million, marking a year-over-year increase of 29.28%. This contributed to the annual value of $202.6 million for FY2024, which is 69.64% up from last year.
  • According to the latest figures from FY2024, Silence Therapeutics' Liabilities and Shareholders Equity is $202.6 million, which was up 69.64% from $119.4 million recorded in FY2023.
  • In the past 5 years, Silence Therapeutics' Liabilities and Shareholders Equity ranged from a high of $202.6 million in FY2024 and a low of $11.6 million during FY2020.
  • In the last 3 years, Silence Therapeutics' Liabilities and Shareholders Equity had a median value of $119.4 million in 2023 and averaged $116.5 million.
  • In the last 5 years, Silence Therapeutics' Liabilities and Shareholders Equity slumped by 56.43% in 2020 and then spiked by 337.27% in 2023.
  • Silence Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $11.6 million in 2020, then increased by 0.84% to $11.7 million in 2021, then surged by 132.86% to $27.3 million in 2022, then spiked by 337.27% to $119.4 million in 2023, then skyrocketed by 69.64% to $202.6 million in 2024.